Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 27Unknown 4Terminated 3Withdrawn 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Vomiting 1Neoplasms, Germ Cell and Embryonal 1Nausea 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Palonosetron × Clear all
NCT01843868 2024-08-07

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Australasian Leukaemia and Lymphoma Group

Phase NA Withdrawn
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Nausea, Vomiting

NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡